This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Currency be a Drag on Nu Skin's (NUS) Q4 Earnings?
by Zacks Equity Research
Nu Skin's (NUS) Q4 results to be hurt by weak gross margin and unfavorable currency translations. Nevertheless, expanding customer base and sales leaders are likely to offer respite.
Earnings Preview: Nu Skin Enterprises (NUS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Nu Skin's Sales Leaders & Customers Revive Lost Sheen?
by Zacks Equity Research
Nu Skin (NUS) grapples with sluggish gross margin and adverse currency trends. Nevertheless, strength in sales leaders and customers are encouraging.
Can Growth in Sales Leaders Uplift Nu Skin Stock in 2019?
by Zacks Equity Research
Nu Skin (NUS) is reeling under soft margins and adverse impacts from currency fluctuations. However, sturdy base of sales leaders and customers is likely to enhance performance.
Why Is Nu Skin (NUS) Up 1.5% Since Last Earnings Report?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moving Average Crossover Alert: Nu Skin Enterprises (NUS)
by Zacks Equity Research
Nu Skin Enterprises (NUS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Nu Skin (NUS) Stock Down on Q3 Earnings Miss, Sales Rise Y/Y
by Zacks Equity Research
Negative currency translation weighs on Nu Skin's (NUS) Q3 performance. Nevertheless, sales leaders and customer count continues to rise.
Nu Skin Enterprises (NUS) Misses Q3 Earnings Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of -2.08% and 1.75%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Sales Leaders & Customers to Aid Nu Skin's (NUS) Q3 Earnings
by Zacks Equity Research
Nu Skin's (NUS) Q3 performance to gain from a sturdy base of sales leaders and customers. Projections for the impending quarter unveil a favorable picture.
Factors Likely to Influence Meredith's (MDP) Q1 Earnings
by Zacks Equity Research
While strategic buyouts and restructuring actions serve as key growth drivers for Meredith (MDP), soft EBITDA margins may be a deterrent.
Will Monster Beverage (MNST) Beat Earnings Estimates in Q3?
by Zacks Equity Research
Monster Beverage (MNST) benefits from product innovation strategy and regular product launches. Latest additions to the Monster brand are likely to generate incremental sales and boost profitability.
Can Keurig Dr Pepper (KDP) Deliver Earnings Beat in Q3?
by Zacks Equity Research
Keurig Dr Pepper (KDP) is poised to gain from DPS' distribution strategy and innovation alongside Keurig's coffee brands and online presence. But, soft CSD trends and higher aluminum prices are woes.
Is Archer Daniels (ADM) Poised for Earnings Beat in Q3?
by Zacks Equity Research
Archer Daniels (ADM) saw a stellar start to 2018, having beaten earnings and sales in the first two quarters of 2018. Do strategies position it for a Q3 beat?
Medifast (MED) Q3 Earnings: Coaches & OPTAVIA are Key Drivers
by Zacks Equity Research
Medifast's (MED) Q3 performance to gain from a sturdy coach base and advancement in the OPTAVIA brand.
Nu Skin Enterprises (NUS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Nu Skin (NUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avon Products (AVP) is on Track for Turnaround: Here's Why
by Zacks Equity Research
Avon (AVP) focuses on boosting growth of Representatives, which is a key factor for the success of its direct-selling business. However, investors are wary of its dismal top and bottom-line trends.
Rising Sales Leaders & Customers Adorn Nu Skin's Performance
by Zacks Equity Research
Nu Skin's (NUS) top line benefits from growth in sales leaders and customers. Further, the company focuses on empowering sales leaders through effective compensations.
Avon Announces Long-Term Financial Targets & Growth Strategy
by Zacks Equity Research
Avon Products (AVP) announces long-term financial targets, backed by its new "Open Up Avon" strategy.
Avon to Consolidate US Operations Into New York Facility
by Zacks Equity Research
Avon (AVP) is making efforts to simplify its U.S. business in a bid to fuel growth. However, this move will lead to head count reductions of roughly 100 employees.
Avon Stock Rallies on Takeover Talks With Brazil's Natura
by Zacks Equity Research
Avon (AVP) gains on rumors of a possible buyout by Natura & Co, the leading Brazilian cosmetics company.
Nu Skin Enterprises Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Nu Skin Enterprises has been struggling lately, but the selling pressure may be coming to an end soon.
5 Reasons Why Helen of Troy Stock Must be in Your Portfolio
by Zacks Equity Research
Helen of Troy (HELE) is likely to keep its stellar show on, evident from its raised earnings outlook for fiscal 2019.
Can Avon's Transformation Updates Aid Representative Growth?
by Zacks Equity Research
Avon (AVP) remains committed to boost growth of Representatives, which is witnessing sluggishness for some time now.
Nu Skin Stock Up 33% in a Year, Sales Leaders a Major Driver
by Zacks Equity Research
Nu Skin (NUS) gains from a sturdy network of sales leaders and customers. These have driven growth in most regional segments.
Coty (COTY) Q4 Earnings In Line, Sales Miss, Stock Down
by Zacks Equity Research
Coty (COTY) matches earnings estimates for fourth-quarter fiscal 2018 while sales lag. Results gain from strength in Luxury and Professional Beauty segments, offset by weakness in Consumer Beauty.